Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NTRP

Neurotrope (NTRP) Stock Price, News & Analysis

Neurotrope logo

About Neurotrope Stock (NASDAQ:NTRP)

Advanced Chart

Key Stats

Today's Range
$1.99
$2.25
50-Day Range
$0.92
$1.05
52-Week Range
$0.68
$3.85
Volume
33,913 shs
Average Volume
28,959 shs
Market Capitalization
$3.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

Neurotrope Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

NTRP MarketRank™: 

Neurotrope scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neurotrope has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Neurotrope has only been the subject of 1 research reports in the past 90 days.

  • Read more about Neurotrope's stock forecast and price target.
  • Earnings Growth

    Earnings for Neurotrope are expected to grow in the coming year, from ($0.78) to $0.12 per share.

  • Price to Book Value per Share Ratio

    Neurotrope has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.87% of the float of Neurotrope has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurotrope has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neurotrope has recently increased by 3.40%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Neurotrope does not currently pay a dividend.

  • Dividend Growth

    Neurotrope does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.87% of the float of Neurotrope has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurotrope has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neurotrope has recently increased by 3.40%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Neurotrope this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Neurotrope to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurotrope insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.40% of the stock of Neurotrope is held by insiders.

  • Percentage Held by Institutions

    Only 3.81% of the stock of Neurotrope is held by institutions.

  • Read more about Neurotrope's insider trading history.
Receive NTRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter.

NTRP Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
NextTrip Inc NTRP
See More Headlines

NTRP Stock Analysis - Frequently Asked Questions

Neurotrope, Inc. (NASDAQ:NTRP) posted its quarterly earnings results on Tuesday, January, 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol-Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE).

Company Calendar

Last Earnings
1/14/2025
Today
4/30/2025
Fiscal Year End
2/28/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Transportation services
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRP
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+147.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
-1,320.29%

Debt

Sales & Book Value

Annual Sales
$630,000.00
Price / Cash Flow
N/A
Book Value
$3.34 per share
Price / Book
0.60

Miscellaneous

Free Float
1,459,000
Market Cap
$3.21 million
Optionable
No Data
Beta
1.69
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:NTRP) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners